2026– date –

GenInnov USA Overview In semiconductor manufacturing, packaging, particularly pitch miniaturization in "vertical competition," is key to performance and cost reduction. Copper-to-copper hybrid bonding is emerging as a major breakthrough,...

The Elec Inc. South Korea Overview Micron will outsource the base die for its custom NVHBM product, developed for NVIDIA and based on HBM4E, anticipating enhanced profitability. NVHBM achieves a 15% reduction in power consumption and up ...

PhotonCap South Korea Overview Samsung has introduced zHBM, an innovative 3D memory architecture concept that directly stacks High Bandwidth Memory (HBM) atop the processor, drastically shortening data paths and integrating dedicated coo...

CHOSUNBIZ South Korea Overview Samsung Electronics is intensifying efforts to manage the escalating heat generated by HBM4E, driven by dramatically expanding interposer sizes for AI semiconductors. The company is adopting Hybrid Copper B...

AMD Newsroom USA Overview AMD has begun sampling its Versal AI Core XQRVC1902 adaptive SoC in an enhanced space-grade organic lidless package, specifically designed for space missions lasting up to 15 years. This novel package incorporat...

MK (Maeil Business Newspaper) South Korea Overview Samsung Electronics is demonstrating strong confidence in supplying higher-specification HBM4 products, anticipating significant price increases next year driven by the rapid performance...

BigGo Finance South Korea Overview As AI semiconductor interposers are projected to expand by up to 40 times, Samsung Electronics is developing Hybrid Copper Bonding (HCB) and Heat Path Block (HPB) technologies to enhance thermal managem...

Psychiatric Times USA Overview Teva Pharmaceutical Industries announced positive post-hoc data from its Phase 3 SOLARIS study of subcutaneous olanzapine (TEV-'749), confirming consistent long-term efficacy and safety for schizophrenia. C...

Pharma Journal India Overview Biocon Biologics' pertuzumab biosimilar, "Pebrilzo," for HER2-positive breast cancer, received a positive opinion recommending marketing authorization from the European Medicines Agency's (EMA) Committee for...

TradingView USA Overview Ionis Pharmaceuticals announced that its FUS-ALS treatment, ulefnersen, met its primary endpoint in the Phase III FUSION trial, signaling a potential breakthrough for this devastating neurodegenerative disease. C...